2.61
1.56%
0.04
アフターアワーズ:
2.66
0.05
+1.92%
前日終値:
$2.57
開ける:
$2.6
24時間の取引高:
55,333
Relative Volume:
0.29
時価総額:
$3.16M
収益:
-
当期純損益:
$-4.74M
株価収益率:
-4.0303
EPS:
-0.6476
ネットキャッシュフロー:
$-3.46M
1週間 パフォーマンス:
+2.76%
1か月 パフォーマンス:
+8.30%
6か月 パフォーマンス:
-49.34%
1年 パフォーマンス:
-67.38%
Lipella Pharmaceuticals Inc Stock (LIPO) Company Profile
名前
Lipella Pharmaceuticals Inc
セクター
電話
412-901-0315
住所
400 N LEXINGTON ST, PITTSBURGH
LIPO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
LIPO
Lipella Pharmaceuticals Inc
|
2.61 | 3.16M | 0 | -4.74M | -3.46M | -0.75 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lipella Pharmaceuticals Inc (LIPO) 最新ニュース
Lipella Pharmaceuticals Inc. announced that it has received $1.722 million in funding - Marketscreener.com
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement - The Manila Times
Spartan Capital Securities, LLC Serves as Sole Placement - GlobeNewswire
Lipella Pharmaceuticals Inc. announced that it expects to receive $6 million in funding - Marketscreener.com
Lipella Pharmaceuticals reschedules special meeting - Investing.com
Lipella Pharmaceuticals reschedules special meeting By Investing.com - Investing.com Canada
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus - GlobeNewswire
Lipella Pharmaceuticals Advances Novel Oral Treatment in Phase 2a Trial, Details Published in CUREUS - StockTitan
Hemorrhagic Cystitis Treatment Market 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Lipella Pharmaceuticals completes dosing for first cohort in LP-310 trial - MSN
Lipella Pharmaceuticals Announces Completion of First - GlobeNewswire
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group - GlobeNewswire
Lipella's LP-310 OLP Treatment Advances in Phase 2a Trial with Promising Safety Data | LIPO Stock News - StockTitan
Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges - MSN
Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023) - Yahoo Finance
LIPO stock touches 52-week low at $2.21 amid market challenges - Investing.com
Lipella Pharmaceuticals Inc (LIPO) Quarterly 10-Q Report - Quartzy
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lipella issued patent by USPTO for liposomal drug delivery platform - TipRanks
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform - The Manila Times
Lipella Pharmaceuticals Secures Extended Market Exclusivity - GlobeNewswire
Lipella Pharma Secures Key Patent for Liposomal Platform, Extends Drug Pipeline Protection to 2035 | LIPO Stock News - StockTitan
China chip index nears 3-year high as TSMC order fuels self-reliance bets - Investing.com
Cathay general bancorp vice chairman sells $2.11 million in stock - Investing.com
Contrasting Wellness Center USA (OTCMKTS:WCUI) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Lipella Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India
Lipella Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com Australia
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - citybiz
Lipella Pharmaceuticals Launching 1-for-8 Reverse Stock Split - Marketscreener.com
Lipella Pharmaceuticals announces 1-for-8 reverse stock split - MSN
Lipella Pharmaceuticals announces 1-for-8 reverse stock split By Investing.com - Investing.com UK
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference - GlobeNewswire
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall - Investing.com India
Lipella Pharmaceuticals faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Biotech Alert: Searches spiking for these stocks today - TipRanks
Ocugen Inc (OCGN) rating initates by Maxim Group - Knox Daily
Potential Price Increase for First Advantage Corp. (FA) After Recent Insider Activity - Knox Daily
Lipella Pharmaceuticals Inc (LIPO) Becoming More Attractive for Investors - Knox Daily
Recent Insider Activity Suggests Potential Gains for KE Holdings Inc ADR (BEKE) - Knox Daily
Lipella Pharmaceuticals Inc [LIPO] is -57.84% lower this YTD. Is it still time to buy? - The DBT News
Allovir (ALVR) Stock Experiences Significant Decline Amid Negati - GuruFocus.com
Huge semiconductor deal has eyes on this tech co 👀 - RagingBull
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform - GlobeNewswire
Interstitial Cystitis Market Size is Set for Rapid Growth as - openPR
Sky Quarry Announces Closing of Public Offering of $6.7 Million - The Manila Times
Lipella Pharmaceuticals Inc (LIPO) 財務データ
収益
当期純利益
現金流量
EPS
Lipella Pharmaceuticals Inc (LIPO) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Kaufman Jonathan H | See remarks below. |
Mar 18 '24 |
Buy |
0.79 |
30,000 |
23,649 |
863,849 |
Kaufman Jonathan H | See remarks below. |
Mar 19 '24 |
Buy |
0.87 |
25,000 |
21,802 |
888,849 |
大文字化:
|
ボリューム (24 時間):